SAB Biotherapeutics Inc (SABS)
3.69
-0.18
(-4.65%)
USD |
NASDAQ |
May 17, 16:00
3.69
0.00 (0.00%)
After-Hours: 20:00
SAB Biotherapeutics Shareholders Equity (Quarterly): 57.30M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 57.30M |
| September 30, 2023 | 15.26M |
| June 30, 2023 | 19.72M |
| March 31, 2023 | 24.40M |
| December 31, 2022 | 31.06M |
| September 30, 2022 | 30.62M |
| Date | Value |
|---|---|
| June 30, 2022 | 37.12M |
| March 31, 2022 | 41.26M |
| December 31, 2021 | 38.55M |
| September 30, 2021 | 106.86M |
| June 30, 2021 | 38.26M |
| December 31, 2020 | 39.01M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
15.26M
Minimum
Sep 2023
106.86M
Maximum
Sep 2021
39.95M
Average
37.69M
Median
Shareholders Equity (Quarterly) Benchmarks
| CEL-SCI Corp | 14.30M |
| AIM ImmunoTech Inc | 10.23M |
| IGC Pharma Inc | 9.053M |
| NovaBay Pharmaceuticals Inc | 0.16M |
| Protalix BioTherapeutics Inc | 29.79M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 83.94M |
| Total Liabilities (Quarterly) | 26.64M |